Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic

While Gilead dropped disappointing data on its Arcus-partnered CD37 inhibitor Wednesday afternoon, the biopharma is making moves to cushion its immune checkpoint pipeline. For $405 million, Gilead will buy MiroBio, an Oxford spinout which just a month ago announced its £80 million Series B round. MiroBio chair Eliot Charles had…

...

Click to view original post